Patents by Inventor Melissa S. Egbertson
Melissa S. Egbertson has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 8211904Abstract: The present invention is directed to spiropiperidine compounds of formula (I) and tautomers thereof, which are inhibitors of the beta-secretase enzyme and that are useful in the treatment of diseases in which the beta-secretase enzyme is involved, such as Alzheimer's disease. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the treatment of such diseases in which the beta-secretase enzyme is involved.Type: GrantFiled: July 14, 2006Date of Patent: July 3, 2012Assignees: Merck, Sharp & Dohme Corp., Sunesis Pharmaceuticals, Inc.Inventors: Craig A. Coburn, Melissa S. Egbertson, Samuel L. Graham, Georgia B. McGaughey, Shaun R. Stauffer, Hemaka A. Rajapakse, Philippe G. Nantermet, Shawn J. Stachel, Wenjin Yang, Wanli Lu, Bruce Fahr
-
Patent number: 8114887Abstract: The present invention is directed to spiropiperidine compounds of formula (I) which are inhibitors of the beta-secretase enzyme and that are useful in the treatment of diseases in which the beta-secretase enzyme is involved, such as Alzheimer's disease. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the treatment of such diseases in which the beta-secretase enzyme is involved.Type: GrantFiled: October 12, 2005Date of Patent: February 14, 2012Assignees: Merck, Sharp & Dohme Corp., Sunesis Pharmaceuticals, Inc.Inventors: James C. Barrow, Craig A. Coburn, Melissa S. Egbertson, Georgia B. McGaughey, Melody A. McWherter, Lou Anne Neilson, Kenneth E. Rittle, Harold G. Selnick, Shaun R. Stauffer, Zhi-Qiang Yang, Wenjin Yang, Wanli Lu, Bruce Fahr
-
Publication number: 20100298342Abstract: The present invention is directed to spiropiperidine compounds of formula (I) and tautomers thereof, which are inhibitors of the beta-secretase enzyme and that are useful in the treatment of diseases in which the beta-secretase enzyme is involved, such as Alzheimer's disease. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the treatment of such diseases in which the beta-secretase enzyme is involved.Type: ApplicationFiled: September 4, 2007Publication date: November 25, 2010Applicants: MERCK & CO., INC., SUNESIS PHARMACEUTICALS, INC.Inventors: Melissa S. Egbertson, Shaun R. Stauffer, Craig A. Coburn, James C. Barrow, Lou Anne Neilson, Jenny M. Wai, Wenjin Yang, Wanli Lu, Bruce Fahr
-
Patent number: 7538112Abstract: Hydroxy-substituted pyrazinopyrrolopyridazine dione compounds are inhibitors of HIV integrase and inhibitors of HIV replication. In one embodiment, the dione compounds are of Formula (I) wherein R1, R2, R3, R4, R5, R6 and R7 are defined herein. The compounds are useful in the prevention and treatment of infection by HIV and in the prevention, delay in the onset, and treatment of AIDS. The compounds are employed against HIV infection and AIDS as compounds per se or in the form of pharmaceutically acceptable salts. The compounds and their salts can be employed as ingredients in pharmaceutical compositions, optionally in combination with other antivirals, immunomodulators, antibiotics or vaccines.Type: GrantFiled: May 3, 2005Date of Patent: May 26, 2009Assignee: Merck & Co., Inc.Inventors: John S. Wai, Joseph P. Vacca, Linghang Zhuang, Boyoung Kim, Terry A. Lyle, Catherine M. Wiscount, Melissa S. Egbertson, Lou Anne Neilson, Mark Embrey, Thorsten E. Fisher, Donnette D. Staas
-
Publication number: 20080287394Abstract: Hydroxy-substituted pyrazinopyrrolopyridazine dione compounds are inhibitors of HIV integrase and inhibitors of HIV replication. In one embodiment, the dione compounds are of Formula (I) wherein R1, R2, R3, R4, R5, R6 and R7 are defined herein. The compounds are useful in the prevention and treatment of infection by HIV and in the prevention, delay in the onset, and treatment of AIDS. The compounds are employed against HIV infection and AIDS as compounds per se or in the form of pharmaceutically acceptable salts. The compounds and their salts can be employed as ingredients in pharmaceutical compositions, optionally in combination with other antivirals, immunomodulators, antibiotics or vaccines.Type: ApplicationFiled: May 3, 2005Publication date: November 20, 2008Applicant: MERCK & CO., INC.Inventors: John S. Wai, Joseph P. Vacca, Linghang Zhuang, Boyoung Kim, Terry A. Lyle, Catherine M. Wiscount, Melissa S. Egbertson, Lou Anne Neilson, Mark Embrey, Thorsten E. Fisher, Donnette D. Staas
-
Patent number: 6919351Abstract: Aza- and polyaza-naphthalenyl carboxamide derivatives including certain quinoline carboxamide and naphthyridine carboxamide derivatives are described as inhibitors of HIV integrase and inhibitors of HIV replication. These compounds are useful in the prevention or treatment of infection by HIV and the treatment of AIDS, as compounds or pharmaceutically acceptable salts, or as ingredients in pharmaceutical compositions, optionally in combination with other antivirals, immunomodulators, antibiotics or vaccines. Methods of preventing, treating or delaying the onset of AIDS and methods of preventing or treating infection by HIV are also described.Type: GrantFiled: October 9, 2001Date of Patent: July 19, 2005Assignee: Merck & Co., Inc.Inventors: Neville J. Anthony, Robert P. Gomez, Steven D. Young, Melissa S. Egbertson, John S. Wai, Jennifer J. Bennett
-
Publication number: 20040034221Abstract: Aza- and polyaza-naphthalenyl carboxamide derivatives including certain quinoline carboxamide and naphthyridine carboxamide derivatives are described as inhibitors of HIV integrase and inhibitors of HIV replication. These compounds are useful in the prevention or treatment of infection by HIV and the treatment of AIDS, as compounds or pharmaceutically acceptable salts, or as ingredients in pharmaceutical compositions, optionally in combination with other antivirals, immunomodulators, antibiotics or vaccines. Methods of preventing, treating or delaying the onset of AIDS and methods of preventing or treating infection by HIV are also described.Type: ApplicationFiled: August 21, 2003Publication date: February 19, 2004Inventors: Neville J Anthony, Robert P. Gomez, Steven D. Young, Melissa S, Egbertson, John S. Wai, Jennifer J. Bennett
-
Publication number: 20030229079Abstract: Certain 1-(aromatic- or heteroaromatic-substituted-3-(heteroaromatic substituted)-1,3-propanediones are described as inhibitors of HIV integrase and inhibitors of HIV replication. These compounds are useful in the prevention or treatment of infection by HIV and the treatment of AIDS, either as compounds, pharmaceutically acceptable salts, pharmaceutical composition ingredients, whether or not in combination with other antivirals, immunomodulators, antibiotics or vaccines. Methods of treating AIDS and methods of preventing or treating infection by HIV are also described.Type: ApplicationFiled: June 6, 2003Publication date: December 11, 2003Inventors: Linda S. Payne, Lekhanh O. Tran, Linghang H. Zhuang, Steven D. Young, Melissa S. Egbertson, John S. Wai, Mark W. Embrey, Thorsten E. Fisher, James P. Guare, H. Marie Langford, Jeffrey Y. Melamed, David L. Clark
-
Patent number: 6040317Abstract: A series of non-peptide derivatives that are antagonists of the fibrinogen IIb/IIIa receptor and thus are platelet anti-aggregation compounds useful in the prevention and treatment of diseases caused by thrombus formation.Type: GrantFiled: December 28, 1998Date of Patent: March 21, 2000Assignee: Merck & Co., Inc.Inventors: Mark E. Duggan, Wasyl Halczenko, Melissa S. Egbertson, George D. Hartman, William L. Laswell
-
Patent number: 5990107Abstract: Fibrinogen receptor antagonist alcohol prodrugs having the structure, for example, of ##STR1## more particularly, ##STR2##Type: GrantFiled: June 26, 1997Date of Patent: November 23, 1999Assignee: Merck & Co., Inc.Inventors: Melissa S. Egbertson, George D. Hartman, William C. Lumma, John S. Wai, Steven D. Young
-
Patent number: 5981584Abstract: Fibrinogen receptor antagonist prodrugs having the structure, for example, of ##STR1## more particularly, ##STR2##Type: GrantFiled: February 3, 1998Date of Patent: November 9, 1999Assignee: Merck & Co., Inc.Inventors: Melissa S. Egbertson, Steve D. Young, George D. Hartman, Jacquelynn J. Cook
-
Patent number: 5945545Abstract: Compounds of this invention have the formula: ##STR1## and pharmaceutically acceptable salts, e.g.Type: GrantFiled: December 11, 1997Date of Patent: August 31, 1999Assignee: Merck & Co., Inc.Inventors: Melissa S. Egbertson, George D. Hartman, Laura M. Vassallo
-
Patent number: 5932582Abstract: Fibrinogen receptor antagonist alcohol prodrugs having the structure, for example, ofX--W--Y--Z--A--Bmore particularly, ##STR1##Type: GrantFiled: June 26, 1997Date of Patent: August 3, 1999Assignee: Merck & Co., Inc.Inventors: Steven D. Young, George D. Hartman, Laura A. Libby, Melissa S. Egbertson, Donald E. Slaughter
-
Patent number: 5880136Abstract: A series of non-peptide derivatives that are antagonists of the fibrinogen IIb/IIIa receptor and thus are platelet anti-aggregation compounds useful in the prevention and treatment of diseases caused by thrombus formation.Type: GrantFiled: August 6, 1998Date of Patent: March 9, 1999Assignee: Merck & Co., Inc.Inventors: Mark E. Duggan, Melissa S. Egbertson, Wasyl Halczenko, George D. Hartman, William L. Laswell
-
Patent number: 5854245Abstract: Fibrinogen receptor antagonists having the structureX--Y--Z--A--Band pharmaceutically acceptable salts, wherein X is a 5, 6 or 7 membered aromatic or nonaromatic ring, and Y is a 5 or 6 membered aromatic ring, e.g.Type: GrantFiled: June 26, 1997Date of Patent: December 29, 1998Assignee: Merck & Co., Inc.Inventors: Mark E. Duggan, Melissa S. Egbertson, George D. Hartman, Steven D. Young, Nathan C. Ihle
-
Patent number: 5852045Abstract: Fibrinogen receptor antagonists having the structure, for example, of ##STR1## for example ##STR2##Type: GrantFiled: October 15, 1996Date of Patent: December 22, 1998Assignee: Merck & Co., Inc.Inventors: Ben C. Askew, George D. Hartman, Mark E. Duggan, Steven D. Young, John H. Hutchinson, John S. Wai, Melissa S. Egbertson, Laura M. Vassallo, Laura A. Libby, Amy E. Krause, Wasyl Halczenko, Nathan C. Ihle
-
Patent number: 5814643Abstract: A series of non-peptide derivatives that are antagonists of the fibrinogen IIb/IIIa receptor and thus are platelet anti-aggregation compounds useful in the prevention and treatment of diseases caused by thrombus formation.Type: GrantFiled: May 22, 1997Date of Patent: September 29, 1998Assignee: Merck & Co., Inc.Inventors: Mark E. Duggan, Melissa S. Egbertson, Wasyl Halczenko, George D. Hartman, William L. Laswell
-
Patent number: 5786373Abstract: Novel fibrinogen receptor antagonists of the formula: X--Y--Z-Aryl-A--B and the pharmaceutically acceptable salts thereof, wherein Aryl is a 5-membered aromatic ring system containing 1 or 2 heteroatoms chosen from N, O or S wherein ring atoms may be unsubstituted or substituted with R.sup.5 and wherein S may be substituted with 0, 1 or 2 oxygen atoms; and X comprises various Nitrogen substituents including aromatic or nonaromatic systems; Y comprises, for example, alkyl or alkylaminocarbonylalkyl groups and Z and A are substituents which when present are independently chosen from alkyl or alkyloxyalkyl or other groups as defined herein; B is (a) or (b). The claimed compounds exhibit fibrinogen receptor antagonist activity, inhibit platelet aggregation and are therefore useful in modulating or preventing thrombus formation.Type: GrantFiled: May 31, 1995Date of Patent: July 28, 1998Assignee: Merck & Co., Inc.Inventors: George D. Hartman, John D. Prugh, Melissa S. Egbertson, Mark E. Duggan, William Hoffman
-
Patent number: 5721253Abstract: Fibrinogen receptor antagonists of the formula: ##STR1## are disclosed for use in inhibiting the binding of fibrinogen to blood platelets and for inhibiting the aggregation of blood platelets.Type: GrantFiled: September 23, 1996Date of Patent: February 24, 1998Assignee: Merck & Co., Inc.Inventors: George D. Hartman, Melissa S. Egbertson, Wasyl Halczenko, Ben Askew
-
Patent number: 5658929Abstract: A series of non-peptide derivatives that are antagonists of the fibrinogen IIb/IIIa receptor and thus are platelet anti-aggregation compounds useful in the prevention and treatment of diseases caused by thrombus formation.Type: GrantFiled: July 21, 1995Date of Patent: August 19, 1997Assignee: Merck & Co., Inc.Inventors: Mark E. Duggan, Melissa S. Egbertson, Wasyl Halczenko, George D. Hartman, William L. Laswell